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In organ culture experiments, the induction of pemphigus 
acantholysis is known to be blocked by the addition of serine 
proteinase inhibitors. Recently, nontoxic synthesized low 
molecular weight proteinase inhibitors have been clinically 
available for the treatment of disseminated intravascular co-
agulation and pancreatitis. To determine if these drugs are 
useful aids to treat patients with pemphigus, we examined 
the effect of w-guanidino ester analogues, i.e., 1) gabexate 
mesilate, 2) camostat mesilate, and 3) nafamostat mesilate, on 
experimental pemphigus acantholysis in both organ culture 
and neonatal BALBlc mice. Furthermore, the effect of 
Since Beutner and Jordon [1] demonstrated that pemphigus serum contained autoantibodies against an intercellular substance of the skin and the mucosa, many investigators have reported pemphigus as an autoimmune disease [for review see Ref 2 and 3]. Experimental models of pem-
phigus, established in skin organ culture and passive transfer into 
neonatal BALBlc mice, revealed the pathogenicity of pemphigus 
antibody [4-10]. The skin organ culture model made it possible to 
investigate further the pathophysiology of pemphigus. Findings 
that the addition of proteinase inhibitors, especially inhibitors of 
serine proteinases, to the culture could inhibit the induction of 
acantholytic changes [6,7]' confirmed the concept of an enzymatic 
mechanism in the pathogenesis after the binding of pemphigus 
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Abbreviations: 
alpha-1-PI: alpha-1-proteinase inhibitor 
DEX: dexamcthasone 
DFP: diisopropyl fluorophosphate 
DTNB: 5,5'-dithiobis(2-nitrobenzoic acid) 
FOY: [ethyl-4-(6-guanidino hexanoyloxy) benzoate)mcthane sulfate 
FOY -305: N, N-dimethylcalbamoylmethyl p-(p-guanidino 
benzoyloxy) phenylacetate methanesulfonatc 
FUT -175: 6-amidino-2-naphthyl p-guanidinobenzoate dimethane-
sulfate 
KSCN: Potassium Thiocyanate 
P A: plasminogen activator 
PBS: phosphate-buffered saline 
PI: proteinase inhibitor 
Z-lys-SBzl: thiobenzyl benzoxycarbonyl-L-Iysinate 
plasma natural proteinase inhibitors (alpha-1-proteinase in-
hibitor) isolated from human plasma was similarly examined. 
Results revealed that synthesized low molecular weight in-
hibitors (drugs) were able to inhibit the induction of acan-
tholysis in organ culture system, but had little or no effect on 
lesion formation in the neonatal mouse system. By contrast, 
alpha-1-proteinase inhibitor could completely inhibit 
acantholysis formation in mice. These findings implied a 
possible new therapeutic approach using proteinase inhibi-
tors for patients with pemphigus.] Invest DermatoI93:173-
177, 1989 
antibody to the surface antigen molecules of stratified epidermal 
cells. Recently it was suggested that elevated levels of plasminogen 
activator (PA) in the epidermis of individuals with pemphigus result 
in enhanced conversion of plasminogen to plasmin, which degrades 
cell surface molecules and causes nonadhesion of epidermal cells [8]. 
In the present study, we applied both a skin organ culture and a 
neonatal BALBlc mice system as experimental pemphigus models 
and examined the effect of clinically usable proteinase inhibitors on 
those models to seek a new therapeutic approach for patients with 
pemphigus. 
MATERIALS AND METHODS 
Preparation of IgG Fractions Serum was obtained separately 
from two typical patients with pemphigus vulgaris. The IgG frac-
tions from pooled sera of the patients were purified by 33% ammo-
nium sulfate precipitation, followed by sequential affinity chroma-
to grapy of lysine-Sepharose and protein A Sepharose CL4B 
(Pharmacia). These IgG fractions were extensively dialyzed against 
either phosphate-buffered saline (PBS), pH 7.4 for use in animal 
studies or Dulbecco's modified Eagle's medium for use in organ 
culture studies and then sterilized by filtration with a 0.45-llm mil-
lipore filter. The concentration ofIgG fractions was adjusted to 7 or 
10 mglml before use. 
Proteinase Inhibitors (PI) 
Drugs Clinically i" Use: 1) gabexate mesilate [11]: [Ethyl-4-(6-
guanidino hexanoyloxy) benzoate] methane sulfate (FOY, Ono 
Pharmaceuticals, Japan); 2) camostat mesilate: N,N-Dimethylcal-
bamoylmethyl p-(p-guanidino benzoyloxy) phenylacetate methan-
esulfonate (FOY -305, Ono Phamaceuticals); 3) mafamostat 
mesilate: 6-Amidino-2-naphthyl p-guanidinobenzoate dimethane-
sulfate (FUT-175, Torii Pharmaceuticals, Japan); and 4) aprotinin 
(Trasylol, Bayer, F.R.G.). 
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Plasma Natural Inhibitors: alpha-I-proteinase inhibitor [12] (alpha-
I-PI, Cutter, Japan). 
Effects of Proteinase Inhibitors on the Activity ofPlasmino-
gen Activator or Plasmin The inhibitory effects of PI (FOY, 
FOY-305, FUT-175, trasylol, alpha-I-PI) on PA or plasmin activ-
ity were examined. Diisopropyl fluorophosphate (DFP) was exam-
ined as a positive control, and normal human serum was used as a 
control for serum inhibitor. The concentrations of PI examined 
were adjusted to the following, which are clinically able to be 
reached in the serum of human individuals: FOY (0.02, 0.1, 0.2, 
0.5,1.0 mg/ml), FOY-305 (0.001, 0.005, 0.D1, 0.05, 0.1 mg/ml), 
alpha-I-PI (0.01, 0.05, 0.1, 0.25, 0.5 mg/ml), trasylol (1 , 10,20, 
50, 100 KlU/ml), DFP (0.5, 2, 5,10,20 mM), and diluted serum 
(1: 50, 1: 25, 1 : 15, 1: 10, 1: 5). Residual activities ofPA or plasmin 
after incubation were measured by the modified method of Cole-
man and Green [13]. 
Effects oj Proteinase Inhibitors on Plasminogen Activator Activity: Each 
PI at various concentrations prepared in 0.12 M glycine-NaOH 
buffer, pH 8.5 or just buffer was incubated with an equal volume of 
PA (5 Plough unit/ml of urokinase, Leo Pharmaceutical, Denmark) 
for 30 min at 37°C. Twenty-five,ul of this mixture was reacted at 
37°C for 30 min with 25 j.ll of 2 j.lM plasminogen, which was 
isolated from healthy human plasma. Then, 950 ,ul of 0.2 mM 
thiobenzyl benzoxycarbonyl-L-lysinate (Z-lys-SBzl, Penninsula 
Laboratory, CA) and 0.2 mM 5,5'-dithiobis (2-nitrobenzoic acid) 
(DTNB, Sigma) prepared in 0.2 M sodium phosphate buffer, pH 
7.5 with 0.01 % Triton X-IOO and 0.2 M NaCI, was added to the 
mixture and further incubated for 15 min at 37°C. After quenching 
the reaction by the addition of 100 j.ll of 0.1 mg/ml SBTI in 0.1 N 
HCl, residual activity was measured by the absorbance at 412 nm, 
and percent inhibition of each PI calculated. We evaluated the 
inhibitory activity of each inhibitor in the linear range of the assay 
using a thiol ester substrate. 
Effects oj Proteinase Inhibitors on Plasmin: Twenty-five j.ll of PI at 
various concentrations prepared in 0.2 M sodium phosphate buffer, 
pH 7.5 or just buffer was initially reacted with 25 j.ll of 2 j.lM 
plasmin for 30 min at 37"C, and the mixture was then incubated at 
37°C for 30 min with 950 j.ll of 0.2 mM Z-lys-SBzl, 0.2 mM 
DTNB, 0.01 % Triton X-I00 in 0.2 M sodium phosphate buffer, 
pH 7.5 with 0.2 M NaCI. The absorbance of these reactants was 
measured at 412 nm and percent inhibition calculated. 
Skin Organ Culture Experiment 
Method oJOrgart Culture: Organ culture of normal human skin was 
carried out by a previously described method [7,14,15]. Briefly, skin 
was sliced to a thickness of approximately 0.5 mm and cut into 
2 X 2 mm pieces. These skin pieces were then placed dermis side 
down on 20 X 20 mm paraffin-edged lens paper rafts. The rafts 
were floated on top of the culture medium (1.0 ml final volume) in 
culture dishes and cultured in a humid atmosphere containing 5% 
CO2 in air for 24, 48, and 72 h. The culture medium used was 
Dulbecco's modified Eagle's medium and contained 7 mg/ml of 
pemphigus IgG with or without PI. After each culture period, the 
skin explants were examined by routine histologic (hematoxylin 
and eosin staining) methods. 
Effects oj Proteinase Inhibitors on Epidermal Acantholysis in Skin Ex-
plants: FOY (final concentrations: 1,5,10 mg/rnl), FOY-305 (0.5, 
1,5 mg/ml), FUT-175 (0.1,0.5,5 mg/ml) were added, respec-
tively, to the cu lture medium in addition to pemphigus IgG. In 10 
other experiments, the incubation of explants with alpha-I-PI was 
started 3 or 12 h before pemphigus IgG was added. 
Animal Experiments 
Passive Transfer oj Pemphigus IgG: Neonatal BALB/c mice were 
obtained within 24 h of birth. Pemphigus IgG fractions were in-
jected intraperitoneally into neonatal BALB/c mice using a 30-
gauge needle in a single administration of 10 mg IgG/g of mouse 
body weight according to the established method [9,10] . To carry 
THE JOURNAL OF INVESTIGATIVE DERMATOLOGY 
out biochemical analysis 3 h after the pemphigus IgG injection, and 
additional biochemical analysis and histologic examination 24 h 
after a like injection, the mice were killed and the whole skin of each 
animal removed. At least five different sites from each removed skin 
were then examined for histologic analysis and a pair of 5-mm 
punch biopsy specimens from the back of each animal were exam-
ined for PA activity. 
Effects oJProteillase Inhibitors in Animal Models: Neonatal BALB/c 
mice received i.p. injection of each PI prepared in PBS 2 h before the 
pemphigus IgG injection. The administered dosages of each PI were 
as fo llows: FOY (133 ,ug/g of mouse body weight), FOY-305 (100 
j.lg/g of body wt), FUT -175 (13 ,ug/g of body wt), alpha-I-PI (1.67 
mg/g of body wt), dexamethasone (DEX; 20 j.lg/g of body wt), and 
PBS (control) were injected, respectively, into mice 2 h before the 
pemphigus IgG injection. Before the administration, all PI and PBS 
were sterilized with a 0.45-j.lm millipore filter. Effects of inhibitors 
on epidermal acantholysis by pemphigus IgG in BALB/c neonatal 
mice were evaluated visually (positive if the presence of Nikolsky 
sign on any part of skin surface was observed) as well as histologi-
cally (positive if at least one of five sites examined showed acantho-
lytic changes) 24 h after injection of pemphigus IgG. 
Plasminogen Activator Assays oJMice Epidermis: The PA assays of the 
epidermis obtained from three mice for each experiment were car-
ried out to examine the effects of PIon the level of epidermal PA. 
Skin samples were taken from the mice at 3- and 24-h intervals after 
the injection of pemphigus IgG with a preinjection of FOY, 
FOY-305, alpha-I -PI, DEX, or PBS. The epidermis of each mouse 
skin was obtained by heating (56 ° C, 30 s) . After twice freezing and 
thawing, the epidermis was homogenized and rotated at 4 ° C for 2 h 
in 0.01 M sodium monophosphate, pH 7.0 to remove serum factors, 
and was centrifuged at 750 g, for 10 min. The pellet was then 
extracted at 4°C for 2 h in 2.0 M Potassium Thiocyanate (KSCN) 
with 0.01% Triton X-I 00 to obtain the P A fraction. After centrifu-
gation of the extracts at 750 g for 10 min, the supernatant was 
dialyzed against 0.12 M glycine-NaOH, pH 8.5. The PA activity 
in extracts was measured with urokinase standard (Leo Pharmaceu-
tical), similar to the method described elsewhere in this manuscript. 
The levels of PA in the epidermis were expressed as Plough unit/ 
mg extractable protein in KSCN extracts. 
RESULTS 
Effects of Proteinase Inhibitor on the Activity of Plasmino-
gen Activator or Plasmin 
Effects 011 Plasminogen Activator Activity: Figure 1 shows the inhibi-
tory effects of PIon the activity of PA. FOY, 0.5 to 1.0 mg/ml, 
inhibited the activity ofPA by 90%, and 0.01 mg/ml of FOY-305 
could produce almost 100% inhibition. High doses of trasylol and 
alpha-I-PI, however, could only slightly inhibit the PA activity. 
Whole serum, used as control of alpha-I-PI, could not inhibit PA. 
Effects 0/1 Plasmin Activity (Fig 2): FOY was able to inhibit the 
activity of plasmin. Even low concentrations of trasylol were able to 
inhibit the plasmin activity. Trasylol had significant inhibitory ef-
fects on plasmin. Alpha-I-PI, 0.5 mg/ml, a concentration about 
one-fifth of human serum level, could inhibit the activity of plasmin 
by 95%. Diluted serum (5 times) was able to inhibit it by only 70%. 
Organ Culture Studies Each cOl1centrationofFOY, FOY-305, 
and FUT -175 could suppress or inhibit the epidermal acantholysis 
in organ culture (Table I). Alpha-I-PI, 2.5 mg/ml, was not able to 
inhibit the acantholysis even if explants were pretreated with alpha-
I-PI 3 or 12 h before the addition of pemphigus IgG. A high con-
centration (25 mg/ml) of alpha-l-PI, however, was able to inhibit 
acantholysis with 3 or 12 h preincubation before the addition of 
pemphigus IgG. The inhibitors, FOY, FOY-305, and FUT-175, 
did not require preincubation to block the acantholysis in explants 
induced by pemphigus IgG. By contrast, alpha-I-PI did require 
preincubation for at least 3 h to achieve inhibition of acantholysis in 
the explants. 
VOL. 93. NO.1 JULY 1989 
~ __ -_----. DFP 
_-::::;:ji=======~c FOY-305 FOY 
100 
.--
90 
80 
70 
60 
50 
40 
30 
20 
trasylol 
10 a , - PI 
I-!c--g::~~::::~;;;~;;~====~ serum 
20 mM DFP 00 
-;:----,:'::-"""*----""'5"'O,....----------,-,!100 K I U /me ~IOI 
~""7'7-;;-';;-------;:O...,\:--------:-'l ~O mg /me FOY ~ 
-::--------"::"0..,.'2:-=5-------:-'0~5 mg /me a,-=;;-
. , 
0 10 20 
0: 1 
, 
0 0. 2 
0 
~~~~,....------,~'~-----~. ~ 
1 : 10 1 : 5 diluted serum 
. . 
0 1 :501:25 
~~~~------,0::-.'::-b5~-------=-'0~ 1 mg /me FOy-=305 . , 0 0.0050 .01 
---<>--
Figure 1. Inhibition ofPA by various inhibitors. Each proteinase inhibitor 
(PI) at various concentrations prepared in 0.12 M glycine- NaOH buffer, 
pH 8.5 or just buffer (control) was mixed with an equal volume of PA (5 
Plough unit/ml urokinase) for 30 min at 37"C. Residual activity of uroki-
nase with 21lM plasminogen was measured in the linear range of the assay 
using thiol ester substrate. Percent inhibition of these PI was shown. 
Animal Studies Lesions could be observed 24 h after the injection 
of pemphigus IgG alone with a positive Nikolsky sign on almost the 
whole skin surface of the experimental animals (Fig 3). The pres-
ence of suprabasilar acantholysis was demonstrated histologically 
each time (Fig 4). Preinjection ofFOY-30S inhibited the Nikolsky 
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Figure 2. Inhibition of plasmin by various inhibitors. Twenty-five III of PI 
or control (0.2 M sodium phosphate buffer, pH 7.5) was reacted with 251ll of 
21lM plasmin for 30 min at 37 °C, and added to 950lll of 0.2 mM Z-lys-SBzl 
and DTNB for 30 min at 37 °C. After measuring the reactants at 412 nm, 
percent inhibition was calculated and shown. 
PROTEINASE INHIBITORS AND EXPERIMENTAL PEMPHIGUS 175 
Table I. Effects of Proteinase Inhibitors on Epidermal 
Acantholysis by Pemphigus IgG in Skin Explants 
Proteinase Inhibitors 
Culture Time (h) 
(final concentration in medium) 24 48 72 
FOY 1 mg/ ml ++ 
5 mg/ ml 
10 mg/ ml 
FOY-305 0.5 mg/ ml ++ 
1 mg/ ml + 
5 mg/ ml 
FUT-175 0.1 mg/ ml +-++ 
0.5 mg/ ml 
5 mg/ ml 
aI-proteinase inhibitor 
2.5 mg/ml + ++ ++ 
25 mg/ ml 
None (pemphigus IgG 7 mg/ ml) + ++ +++ 
FOY. FOY-305. FUT-175 were added respectively to the culture medium besides 
pemphigus IgG. Alpha-I-PI was added to the culture medium 3 h before the addition of 
pemphigus IgG. Acantholysis positive at 10-30% (+). 30-70% (++). 70 - 100% 
(+++) of epidermis in the histologic section. Acantholysis negative (-). 
Figure 3. Nikolsky sign was observed 24 h after pemphigus IgG injectiOll 
alone into neonatal BALB/c mice. 
Figure 4. Suprabasilar acantholysis was found 24 h after pemphigus IgG 
injection alone into neonatal BALB/c mice. (X200) 
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sign in all 10 animals and was able to suppress the appearance of 
acantholysis to 40% (positive in 4 of 10 animals). In addition, even 
in the animals pretreated with FOY -305 where it was classed as 
positive, acantholysis was observed in one or two at most of the five 
biopsies per animal (data not shown) . FOY, FUT-175 suppressed 
the appearance of the Nikolsky sign to some extent, but had no 
effect on acantho lysis. In the animals with pemphigus IgG plus 
FOY, FUT-175, or DEX, acantholysis was observed in 4 or 5 biop-
sies of five per animal (data not shown). Only preinjection of2.5 mg 
alpha-i-PI could inhibit both Nikolsky and acantholysis com-
pletely in 6 animals (Table II). We initially examined the effects of 
alpha-1-PI at an administration of 0.25 and 0.5 mg per mouse (167 
J1.g and 334 J1.g of alpha-I-PI per gram of mouse body wt), however, 
no inhibitory change was observed. 
PA Assays There was no significant plasminogen-independent 
activity in the samples measured. Epidermal PA levels of untreated 
mice were measured at 182 ± 23 mPu/mg extractable protein 
(mean ± standard deviation, n = 12). The PA levels of PBS pre-
treated mice that received an injection of normal human IgG were 
also measured as a reference and were recorded at 63 ± 26 mPu/mg 
protein (3 h after the IgG injection) and 195 ± 21 mPu/mg protein 
(24 h). As a control, the PA level of PBS pretreated mice, 3 h after 
the injection of pemphigus IgG, was determined to be 98 ± 17 
rnPu/mg protein and was increased to 278 ± 21 mPu/mg protein 
24 h after the same injection. The injection of pemphigus IgG 
en hanced the PA activity by 56% (3 h) and by 43% (24 h after the 
injection of IgG) when compared with the PA level of normal IgG 
injected mice. Pretreatment of mice with alpha-1-PI reduced the 
PA activity by 33% when PA activities were compared with the 
control (24 h), although FOY -305 had a less-reducing effect (by 
13%) on the activity of the control. The P A levels of mice that 
received alpha-I-PI or FOY -305 3 h after pemphigus IgG injection 
was similar to that of mice that received PBS. On the other hand, 
DEX reduced the PA activity by 65% 3 h after dle injection of 
pemphigus IgG, although the PA activity was reduced by only 21 % 
24 h after the same injection (Fig 5). 
DISCUSSION 
The pathogenicity of pemphigus autoantibody has been studied by 
many investigators using experimental methods of skin organ cul-
ture, epidermal cell culture, or passive transfer into newborn mice. 
In skin organ culture 6ystem, it has been shown that pemphigus 
antibody can induce acantholytic changes without the participation 
of complement [5 ,7]. Because the induction of acantholysis by pem-
phigus antibody in skin explants was blocked by the addition of 
proteinase inhibitors, such as soybean trypsin inhibitor, lima bean 
trypsin inhibitor, and aprotinin, it was believed that proteinase(s) 
were involved in this phenomenon [2,7,8]. In an experiment with 
keratinocyte cultures, incubation of the culture with pemphigus 
Table II. Effects of Inhibitors on Epidermal Acantholysis by 
Pemphigus IgG in BALB/c Neonatal Mice 
Appearance of Appearance of 
Proteinase Nikolsky' Acantholysis' 
Inhibitors Dose/Mouse (% ) (%) 
FOY 200 Jig 4/6 (67%) 6/6 (+) (100%) 
FOY-30s 150 Jig 0/10 (0%) 4/10 (+) (40%) 
FUT-17s 20 Jig 3/66 (50%) 6/6 (+) (100%) 
<XI-proteinase 
inhibitor 2.5 mg 0/6 (00/0) 0/6 (+) (0%) 
Dexamethasone 3/3 (100%) 3/3 (+) (100%) 
Control (0.9% NaCl) 26/30 (+) (87%) 
Neonatal BALBlc mice were given i.p. injection of each PI prepared in PBS 2 h 
before the injection of pemphigus IgG. Effects of PI were eva luated visuall y as well as 
histologically 24 h after injection of pemphigus IgG. 
•. ' The number under" Appearance of Nikolsky' (Acantholysis')" refers to the num-
ber of animal tested. 
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Figure 5_ P A activity in mice epidermis. P A assays of the epidermis ob-
tained from mice 3 and 24 h after the injection of pemphigus IgG (P-IgG) 
were carried out using a thiol ester substrate. Each mouse was administered 
an i.p. injection of PI, DEX, or PBS (control) 2 h before the P-IgG injection. 
The levels ofPA in the epidermis were expressed as Plough unit/mg extract-
able protein in KSCN extracts. The base line level ofPA in mouse epidermis 
was shown as "Untreated." The PA levels of the reference were obtained 
from mice pretreated with PBS and normal human IgG and are shown as 
"PBS + N - IgG." Each value was determined from 6 mice per experiment 
in a duplicate assay (n = 12). Results expressed as mean ± 1 SD and I-test 
against "PBS + P - IgG (at 3 and 24 h, respectively)" are shown (* = p < 
0.01, •• = P < 0.05: statistically significant). 
antibody induced high levels of PA after the binding of pemphigus 
antibody to the surface antigen of cultured epidermal cells (8]. Very 
recently, the pivotal role ofPA ill acantholysis was demonstrated by 
results that showed that the acantholysis induced by pemphigus 
antibody was blocked by rabbit antiurokinase antibody, which was 
able to inhibit epidermal PA activity [16] . It is now speculated that 
the binding of pemphigus autoantibody to the surface antigen of 
epidermal cells stimulates the production of plasminogen activator, 
and then in the presence of plasminogen the increased levels of P A 
result in enhanced conversion of plasminogen to plasmin [16]. 
Therefore, plasmin is believed to be responsible for the induction of 
pemphigus acantholysis. Based on the concept of such an enzymatic 
mechanism, we attempted to examine the effect of nontoxic, syn-
thetic proteinase inhibitors already in use as a drug and natural 
inhibitors present in the plasma on the appearance of characteristic 
pemphigus features such as acantholysis or Nikolsky's phenome-
non, or both, in the experimental model for pemphigus. Synthetic 
proteinase inhibitors examined in our experiments were all {J.}-
guanidino ester analogues and their usefulness has already been 
established for the treatment of disseminate intravascular coagula-
tion and pancreatitis. Natural inhibitors by themselves are also con-
sidered clinically applicable to patients with inhibitor deficiency. 
Initially, we examined the inhibition profiles of various proteinase 
inhibitors against the activity of PA and plasmin. As shown in Fig-
ures 1 and 2, they appeared to be classified into two groups. Inhibi-
tors in the first group (FOY, DFP) were potent inhibitors of both 
PA and plasmin and those in the second group (trasylol, alpha-1-PI) 
were potent inhibitors of only plasmin. FOY-305 and FUT-175 
showed similar inhibition profiles to those of FOY, although they 
had an inhibitory activity approximately 10 times stronger to both 
PA and plasmin than FOY did. These results indicate that all the 
inhibitors tested were able to block the PA/plasmin system in vitro. 
To evaluate the inhibitory effect of these inhibitors on the forma-
tion of epidermal acantholysis, we initially added them to the organ 
culture model (Table I). The experimental results revealed that 
synthetic inhibitors and a natural inhibitor were able to block the 
epidermal acantholysis induced by pemphigus IgG. However, the 
former was much more able than the latter to inhibit the formation 
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of acantholysis. To get a complete inhibition by alpha-I-PI, a high 
concentration of this inhibitor (25 mg/ml) was necessary, requiring 
preincubation of skin explants for 3 -12 h with the inhibitor before 
being exposed to pemphigus IgG. On the other hand, the results in 
the neonatal BALB/c mice model were somewhat different from 
that in the skin organ culture model, showing that preinjection of 
alpha-I -PI achieved the greatest inhibitory effect on acantholysis 
formation at a 100% efficiency. Preinjection of FOY-305 sup-
pressed the appeara nce of acantholysis to 40%, although this was 
not as efficient as alpha- I-PI. The discrepancy between the results 
of the two experimental models with regard to the effect of inhibi-
tors on epidermal acantholysis may be due to the differences in the 
skin of human and neonatal mouse. An important factor contribut-
ing to this may be due to the kind of experimental animal used, the 
neonatal mouse. Because of the average body weight of the animals 
used, 1.5 g, in comparison with humans, we were limited to the 
followin g dosages: 200 f..lg FOY, 150 f..lg FOY-305, and 20 f..lg 
FUT-175. Any dosage administered exceeding those previously 
mentioned would probably have resulted in the death of the neona-
tal mouse. Therefore, the potential effect of the proteinase inhibi-
tors may have been influenced by the limitation placed on the dos-
age levels. From the point of view of safety, alpha-I-PI is more 
physiologic and may be much safer than synthetic inhibitors. Effects 
of DE X on experimental pemphigus in neonatal mice were reported 
by Anhalt et al [17]. According to their study, DEX could not 
inhibit acantholysis in mice that had recieved pemphigus IgG, al-
though it decreased PA levels in the epidermis of the same mice. In 
our experiment, decreased PA levels in mouse epidermis by DEX 
were observed 3 h after the injection of pemphigus IgG. However, 
at 24 h P A levels in mouse epidermis were not as low as those at 3 h 
by DEX (65% at 3 h and 21 % at 24 h). This result suggested that the 
effect of DEX on PA activity may be time-dependent. In control 
experiments, 3 h after iqiection of pemphigus IgG to the mouse 
with or without PBS preinjection, a significant decrease of the P A 
levels 3 h after the injection of pemphigus IgG was observed to 
98 ± 17 mPu/mg protein. W e thought that this phenomenon was 
not pemphigus IgG-related because the PA levels in the epidermis 
of the mice 3 h after the normal IgG injection had also decreased to 
63 ± 26 mPu/mg protein. This may be due to the systemic admin-
istration of a large quantity of serum protein, IgG. In neonatal mice 
that had received preinjection of alpha-I-PI, neither epidermal 
acantholysis nor Nikolsky's sign was observed, and the PA level was 
slightly lower than that in control. It may not be of significance to 
extract and compare the activities ofPA in the lesional epidermis of 
acantholysis positive and negative mice, as the proteolytic events of 
P A and plasmin system in the pathophysiology are thought to be 
that of microenvironmental phenomenon very localized on the epi-
dermal cell surface or intracellular space. Our firm finding is that a 
number of drugs that inhibit the PA/plasmin system in vitro can 
also be shown to have pharmacologic effects on the pemphigus IgG 
acantholysis model both in the in vitro human skin organ culture 
system and in an in vivo neonatal mouse model , although the inhib-
itory effects differ somewhat between the two systems. This result 
implies a possible new approach using proteinase inhibitors in the 
treatment of pemphigus patients. 
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